Microbix Biosystems Inc. (MBXBF) is a life sciences innovator, manufacturer, and exporter that focuses on biological products for the global diagnostics industry. News about Microbix often centers on developments in its antigen manufacturing capabilities, expansion of its quality assessment products (QAPs™), and updates on its reference materials (QUANTDx™) used by clinical laboratories and diagnostics makers.
Investors and industry professionals following Microbix news can expect updates on product commercialization, such as the company’s recombinant nucleocapsid antigen of the SARS-CoV-2 virus for use in QAPs and by test manufacturers. Coverage may also include announcements related to its expertise in native viral antigens, new applications of its QAPs and reference materials in proficiency testing and external quality assessment programs, and developments in reagents and media that support diagnostic testing, including DxTM™ for patient-sample collection.
Microbix news releases also address regulatory and disclosure matters, including interactions with securities regulators about continuous disclosure practices and the use of non-IFRS financial measures. These items provide context about how the company presents its financial and operational information to investors.
Because Microbix supplies antigens to approximately 100 diagnostics makers and distributes QAPs in over 30 countries, its news can be relevant to stakeholders across the diagnostics value chain. By monitoring this page, readers can review announcements about product launches, manufacturing capabilities, quality and regulatory accreditations, and other corporate communications that shape the company’s role in the diagnostics and life sciences sectors.
Microbix Biosystems (MBXBF) will attend and present at the European Meeting on Molecular Diagnostics, taking place November 4–6, 2026. The meeting will be held in Noordwijk, The Netherlands.
Its poster examines synthetic DNA- and RNA-based quality assessment products, materials used to check diagnostic testing workflows, for hepatitis C molecular testing. The presentation covers controls designed for point-of-need testing and laboratory testing. Dr. Amer Alagic, Director of R&D and the poster's lead author, will present. Microbix will also attend scientific and clinical-care discussions relevant to its business and clients.
Microbix Biosystems (MBXBF) is reviewing new U.S. tariffs on Canadian products that appear to cover its QAPs quality assessment products.
The 50% tariffs apply from 12:01 a.m. on October 30, 2026, and are collected from U.S. buyers or importers, increasing end-user costs. For the nine months ended June 30, 2026, QAPs sales were C$4.2 million, including an estimated C$3.4 million to U.S.-based clients. Total revenue from U.S.-based clients was C$5.5 million.
Microbix believes U.S.-made alternatives cannot readily replace QAPs because of their complexity and extensive validation requirements in customer testing workflows. If tariffs persist longer term, U.S. customers may seek cost sharing or consider domestic manufacturers. Microbix plans to update its forward-looking information after assessing the impacts and whether trade negotiations reduce or eliminate the tariffs.
Microbix Biosystems (MBXBF) will present to investors at the Planet MicroCap Toronto 2026 Investment Conference on October 27–29, 2026.
CEO Cameron Groome will give the presentation and hold one-on-one investor meetings at the Arcadian Loft in Toronto. Presentation slides will be posted on the Microbix website alongside its business information and financial disclosures.
Microbix Biosystems (MBXBF) will present research on a synthetic vaginal matrix for HPV testing at IPVS 2026, taking place October 22–25. The International Papillomavirus Society conference will be held in Athens, Greece. The jointly authored poster describes development of a renewable synthetic material for use with dry quality controls, which help laboratories check test performance.
In testing on an FDA-approved HPV genotyping assay, dry controls reconstituted in the synthetic matrix detected the expected HPV types and performed comparably to controls used with pooled vaginal material from healthy donors, with no signs of assay interference. The authors describe the approach as a potential tool for verifying HPV testing, including self-collected specimens. Commercial availability remains prospective. Microbix will make the poster available on its website after the presentation.
Microbix Biosystems (MBXBF) will give a keynote presentation at MasterControl's Masters Summit 2026, held October 12–15 in Salt Lake City, Utah. IT Manager Dmytro Panchenko and QC Project Lead Semiramida (Nina) Markosyan will discuss the company's adoption and use of MasterControl's electronic quality management system, including achievements and implementation challenges, before 600+ specialist attendees.
Three Microbix team members will also attend advanced and updated training. Selected in 2022 and since substantively onboarded, the software supports operational, research, manufacturing and quality functions alongside electronic manufacturing and testing records systems.
Microbix Biosystems (MBXBF) will present to investors at the Cantech Investment Conference in Toronto on October 8, 2026. CEO Cameron Groome will give the presentation and hold one-on-one meetings with growth company investors.
The conference, organized by Cantech Media, will take place at the Arcadian Loft, 401 Bay Street. Presentation slides will be posted on the Microbix website alongside other business information and financial disclosures.
Microbix Biosystems (MBXBF) will present to investors at the Muskoka Capital Event in Minett, Ontario, from September 25 to 27, 2025. CEO Cameron Groome and Director of Product Management Pavel Zhelev plan to conduct 18 one-on-one meetings with growth-company investors during the formal part of the conference. Presentation slides will be posted on the company’s website alongside other business information and financial disclosures.
Microbix is a Canadian life sciences company with fiscal 2025 revenues of C$18.6 million and about 120 employees, providing proprietary antigens, QAPs quality assessment products, and QUANTDx reference materials to diagnostics manufacturers and clinical laboratories in more than 30 countries.
Microbix Biosystems (MBXBF) has completed formal qualification as a supplier to five major in-vitro diagnostics (IVD) manufacturers that are each among the ten largest Dx Test-Makers by revenue. These companies have completed multi-step audits of Microbix’s manufacturing, quality, ISO compliance, and related systems.
Qualification enables Microbix to supply products across its antigens, QAPs, ONBOARDx kits, QUANTDx reference materials, and reagents. While this does not guarantee contracts, Microbix expects improved access to new project opportunities with these large manufacturers and believes this vetted status may also support business with smaller diagnostics companies. The company reported C$ 18.6 million of revenue in its latest fiscal year 2025.
Microbix Biosystems (TSX:MBX, OTCQX:MBXBF) reported Q3 fiscal 2026 revenue of $4.1 million, up 17% year-over-year, driven by 20% growth in antigen sales to $2.2 million and 13% growth in QAPs to $1.7 million. Q3 gross margin rose to 54% from 41%.
According to Microbix, Q3 operating and net loss narrowed to $0.81 million from $1.64 million, and cash used in operations improved to $0.47 million from $1.92 million. For the nine months, revenue fell 21% to $11.7 million, mainly from a >$4 million decline in China antigen sales, contributing to a YTD net loss of $3.4 million. The company ended Q3 with $7.2 million in cash, a current ratio of 6.89, and a debt-to-equity ratio of 0.40.
Microbix Biosystems (TSX:MBX, OTCQX:MBXBF) plans to file its financial statements, management discussion and analysis, and news release for Q3 fiscal 2026 (quarter ended June 30, 2026) before the start of trading on August 13, 2026.
On the same day at 10:00 AM ET, Microbix intends to host a results webinar featuring its CEO, CFO, and COO, moderated by Adelaide Capital, with live access via Zoom registration and YouTube, and a replay to follow. The company also highlights its 2025 revenues of C$18.6 million and its global portfolio of diagnostic ingredients, quality assessment products (QAPs, QUANTDx), and other proprietary life sciences technologies.